TAKEDA BCG MATRIX TEMPLATE RESEARCH B_183 Divesting these allows Scandit to

Divesting these allows Scandit to concentrate resources on core

with an order backlog of £500M

0 billion where bio-actives grow ~9-12% CAGR (2023-2028)

Value Proposition Element Description Impact in 2024 Clean Energy Source Fusion provides sustainable power without CO2 emissions

1M (+38%) Workforce data points 50M Internal mobility uplift +12% External hire spend cut ~22% Compliance spend $120M EMEA/APAC revenue growth ~40% YoY

TAKEDA BCG MATRIX TEMPLATE RESEARCH B_183 Divesting these allows Scandit toSee the Bigger Picture Takeda's BCG Matrix snapshot highlights which therapeutic areas are growth leaders, steady cash generators, or strategic liabilities essential for allocating R&D and commercial capital in a volatile pharma landscape. This preview maps high level placements and signals where management should double down or divest amid patent cliffs and M&A activity. Purchase the full BCG Matrix for quadrant by quadrant data, actionable